Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NewishT for High-Risk Hepatocellular Carcinoma
NCT05352646Phase 1Recruiting
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Autologous memory lymphocyte therapy in hepatocellular carcinoma (HCC), sponsored by Newish Technology (Beijing) Co., Ltd. Primary endpoint: Dose-Limiting Toxicity at 14 days. Started Jul 2022; status: recruiting.
02
Drugs
Autologous memory lymphocyte therapy
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05352646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05352646.